Format

Send to

Choose Destination
Curr Opin Struct Biol. 2013 Jun;23(3):393-402. doi: 10.1016/j.sbi.2013.03.008. Epub 2013 Jun 1.

Advances in recombinant protein expression for use in pharmaceutical research.

Author information

1
Novartis Pharma AG, Expertise Platform Proteases, Fabrikstrasse-16, Basel CH-4002, Switzerland.

Abstract

Protein production for structural and biophysical studies, functional assays, biomarkers, mechanistic studies in vitro and in vivo, but also for therapeutic applications in pharma, biotech and academia has evolved into a mature discipline in recent years. Due to the increased emphasis on biopharmaceuticals, the growing demand for proteins used for structural and biophysical studies, the impact of genomics technologies on the analysis of large sets of structurally diverse proteins, and the increasing complexity of disease targets, the interest in innovative approaches for the expression, purification and characterisation of recombinant proteins has steadily increased over the years. In this review, we summarise recent developments in the field of recombinant protein expression for research use in pharma, biotech and academia. We focus mostly on the latest developments for protein expression in the most widely used expression systems: Escherichia coli (E. coli), insect cell expression using the Baculovirus Expression Vector System (BEVS) and, finally, transient and stable expression of recombinant proteins in mammalian cells.

PMID:
23731801
DOI:
10.1016/j.sbi.2013.03.008
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center